8 years of follow-up in the CheckMate 214 trial
Yüksel Ürün shared a paper by Nizar M. Tannir et al. on X:
“Nivolumab + ipilimumab (NIVO+IPI) shows superior overall survival and durable response compared to sunitinib (SUN) in advanced renal cell carcinoma (aRCC) patients after 8 years of follow-up in the CheckMate 214 trial.”
Source: Yüksel Ürün/X
Authors: N.M. Tannir, L. Albigès, D.F. McDermott, M. Burotto, T.K. Choueiri, H.J. Hammers, P. Barthélémy, E.R. Plimack, C. Porta, S. George, F. Donskov, M.B. Atkins, H. Gurney, C.K. Kollmannsberger, M.-O. Grimm, C. Barrios, Y. Tomita, D. Castellano, V. Grünwald, B.I. Rini, R. Jiang, H. Desilva, V. Federov, C.-W. Lee, R.J. Motzer
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023